Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes
- PMID: 2288874
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes
Abstract
The majority of the p53 genes derived from human colorectal carcinomas contain point mutations. A significant number of these mutations occur in or around amino acids 143, 175, 273, or 281. Experiments presented here demonstrate for the first time that p53 DNA clones containing any one of these mutations cooperate with the activated ras oncogene to transform primary rat embryo cells in culture. These transformed cells produce elevated levels of the human p53 protein, which has extended half-lives (1.5-7 h), as compared to the wild-type human p53 protein (20-30 min). The p53 mutant with an alteration at residue 175 (p53-175H) binds tightly to the cellular heat shock protein, hsc70. In contrast, the p53 mutants possessing mutations at either residue 273 or 281 (p53-273H/281G) do not bind detectably to this heat shock protein and generally are less efficient at forming transformed foci in culture. The transformed cell lines are tumorigenic in nude mice. Thus, two classes of p53 mutant proteins can be distinguished: p53-175H, which cooperates with ras efficiently and binds to hsc70, and p53-273H/281G, which has a reduced efficiency of transformed foci formation and does not bind hsc70. This demonstrates that complex formation between mutant p53 and hsc70 is not required for p53-mediated transformation, but rather it facilitates this function, perhaps by ensuring sequestration of the endogenous wild-type p53 protein. The positive effect on cell proliferation by these mutant p53 proteins is consistent with a role for activated p53 mutants in the genesis of colorectal carcinomas.
Similar articles
-
The p53 tumor suppressor gene and gene product.Princess Takamatsu Symp. 1989;20:221-30. Princess Takamatsu Symp. 1989. PMID: 2488233 Review.
-
The properties of p53 proteins selected for the loss of suppression of transformation.Cell Growth Differ. 1994 Jan;5(1):61-71. Cell Growth Differ. 1994. PMID: 8123594
-
Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene.Oncogene. 1995 Oct 5;11(7):1339-45. Oncogene. 1995. PMID: 7478555
-
The gene for the rat heat-shock cognate, hsc70, can suppress oncogene-mediated transformation.Cell Growth Differ. 1992 Nov;3(11):803-9. Cell Growth Differ. 1992. PMID: 1467307
-
Biochemical properties of the growth suppressor/oncoprotein p53.Oncogene. 1992 Sep;7(9):1673-80. Oncogene. 1992. PMID: 1501881 Review.
Cited by
-
MDM-2 protein expression in nasopharyngeal carcinomas. Comparative study with p53 protein expression.Clin Mol Pathol. 1995 Dec;48(6):M322-5. doi: 10.1136/mp.48.6.m322. Clin Mol Pathol. 1995. PMID: 16696032 Free PMC article.
-
Tunneling-nanotube development in astrocytes depends on p53 activation.Cell Death Differ. 2011 Apr;18(4):732-42. doi: 10.1038/cdd.2010.147. Epub 2010 Nov 26. Cell Death Differ. 2011. PMID: 21113142 Free PMC article.
-
Adenovirus E1A-regulated transcription factor p120E4F inhibits cell growth and induces the stabilization of the cdk inhibitor p21WAF1.Mol Cell Biol. 1998 Jan;18(1):459-67. doi: 10.1128/MCB.18.1.459. Mol Cell Biol. 1998. PMID: 9418893 Free PMC article.
-
Demystified ... p53.Mol Pathol. 1998 Oct;51(5):248-53. doi: 10.1136/mp.51.5.248. Mol Pathol. 1998. PMID: 10193518 Free PMC article. Review. No abstract available.
-
p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.Proc Natl Acad Sci U S A. 1996 May 14;93(10):4781-6. doi: 10.1073/pnas.93.10.4781. Proc Natl Acad Sci U S A. 1996. PMID: 8643480 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous